Expanding Continuous Manufacturing at Pfizer, Enabling High Drug Load Formulations via Wet Granulation Technology

The Pfizer Continuous Manufacturing Module (PCMM) is capable of manufacturing tablets via either direct compression (DC) or wet granulation (WG).  The initial commercialization of Daurismo^TM (Glasdegib) and Cibinqo^TM (Abrocitinib) was achieved in 2018 and 2021 respectively using a PCMM- DC continuous direct compression approach. In this presentation we will discuss the development and application of PCMM-WG technology to Pfizer’s third NCE small molecule compound.  We will discuss our rational for drug product design, components of the emerging control strategy, and an overview of multi variate experimental and modeling efforts supporting this effort.

Presented by Travis Powell, Senior Principal Scientist at Pfizer

Travis is a Senior Principal Scientist at Pfizer with 9 years of experience in process and formulation development for oral drug products. He holds a PhD in physical chemistry from the University of Wisconsin-Madison. 

Followed by a live Question and Answer session